Glyburide Liquisolid Compacts Case Study

1308 Words 6 Pages
To meet the ever increasing demands for improved quality of life, a number of pharmaceutical researchers have developed a variety of dosage forms and the oral route has always been the most preferred means of drug administration due to the ease, high patient compliance and low cost of production. In spite of a variety of dosage forms, tablets are most commonly adopted dosage form. The class II drugs have low solubility issues which results in poor dissolution rate and bioavailability[1,2].
Different methods have been employed to enhance the dissolution profile and also increase the bioavailability of water insoluble drugs. Solubility is one of the important parameter to achieve desired concentration of the drug to accomplish pharmacological
…show more content…
It was calculated using eqn. Lf = ΦCA + ΦCO ⋅ (1/ R)
The Lf factor was then used to calculate the required amount of carrier (Q) and coating material (q). Lf = W/Q q = Q/R
Experimental design of Glyburide Liquisolid compacts:[13]
The optimization of Glyburide liquisolid compacts was carried out by taking into consideration the conc. of drug in Transcutol HP and amount of carrier: coating material ratio as independent variables and the disintegration time and cumulative percentage drug release at 60 min as dependent variables. The variables operating range for Transcutol HP was 5-10 were 5 is low level and 10 is high level and variable operating range for carrier: coating material ratio is in the range of 10:1-20:1 were 10:1 is low level and 20:1 is high level. The experimental runs were generated using Central composite design as shown in Table
…show more content…
For estimating weight variation, 20 tablets of each formulation were weighed using an electronic weighing balance. The disintegration time of all formulations was carried out using disintegration test apparatus. The hardness of tablets prepared was evaluated using monsanto hardness tester (Campbell Electronics, Mumbai, India), the mean hardness of each formulation was determined. Friability of the prepared tablets was measured using tablet friability tester (Electrolab, Mumbai, India) and the percentage loss in weights were calculated and taken as a measure of friability[16]. The drug content in different liquisolid tablet formulations was determined by accurately weighing 10 tablets and powdered. The blend equivalent to 5mg of glyburide was weighed and dissolved in sufficient quantity of 0.1N HCl and assayed at 231nm, using UV spectrophotometer[17].
In-vitro dissolution studies:
The in vitro dissolution of Glyburide from the liquisolid tablets was carried out using USP Type II dissolution apparatus. The test was performed using 900 ml of 0.1N HCl maintained at 37ºC ± 0.5ºC temperature and a stirring speed of 50 rpm. 10ml of the medium was withdrawn at 5, 10, 15, 30, 45 and 60 minutes and same amount was replaced with fresh medium to maintain constant volume. The absorbance of the withdrawn media is analyzed at 231 nm using UV spectrophotometer

Related Documents